Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes

被引：11

作者：

Kishimoto M. ^{[1
]}

Noda M. ^{[1
]}

机构：

[1] Department of Diabetes and Metabolic Medicine, Center Hospital, and Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku

来源：

Diabetes Therapy | 2012年 / 3卷 / 1期

关键词：

C-peptide; Continuous glucose monitoring; Glucagon-like peptide 1; Glucosedependent insulinotropic peptide; Insulin; Miglitol; Sitagliptin; Type; 2; diabetes;

D O I：

10.1007/s13300-012-0011-x

中图分类号：

学科分类号：

摘要：

Introduction: To examine the efficacy of sitagliptin and miglitol when added to ongoing insulin treatment in a patient with type 2 diabetes who had undergone partial gastrectomy. Methods: Continuous glucose monitoring (CGM) was performed and either sitagliptin or miglitol, or both, were added to fixed-dose insulin therapy. Blood was drawn at 0, 30, 60, and 120 min after breakfast, and C-peptide, glucagon, glucagon-like peptide (GLP)-1, and glucose-dependent insulinotropic peptide (GIP) were measured. Results: CGM showed that compared to insulin alone, the addition of either sitagliptin or miglitol, or both, to insulin achieved better glucose control. Compared to insulin alone, early postprandial increments in plasma C-peptide levels and suppressed glucagon levels were observed when sitagliptin was added. Glucagon suppression was even more prominent when both sitagliptin and miglitol were added. Compared to insulin alone, GLP-1 levels were higher during the early postprandial stage when sitagliptin or miglitol was added and even higher when both were added. GIP levels decreased when sitagliptin or miglitol, or both, were added to insulin therapy. Conclusion: The authors showed that the addition of sitagliptin or miglitol, or both, was effective in this insulin-treated patient with diabetes who had undergone gastrectomy. © The Author(s) 2012.

引用

页码：1 / 9

页数：8

共 29 条

[1] Makimattila S., Nikkila K., Yki-Jarvinen H., Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus, Diabetologia., 42, pp. 406-412, (1999)
[2] Drucker D.J., The role of gut hormones in glucose homeostasis, J Clin Invest., 117, pp. 24-32, (2007)
[3] Meier J.J., Nauck M.A., Incretins and the development of type 2 diabetes, Curr Diab Rep., 6, pp. 194-201, (2006)
[4] Holst J.J., The physiology of glucagon-like peptide 1, Physiol Rev., 87, pp. 1409-1439, (2007)
[5] Merck Sharpe & Dohme
[6] Herman G.A., Bergman A., Stevens C., Et al., Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes, J Clin Endocrinol Metab., 91, pp. 4612-4619, (2006)
[7] Karasik A., Aschner P., Katzeff H., Davies M.J., Stein P.P., Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: A review of recent clinical trials, Curr Med Res Opin., 24, pp. 489-496, (2008)
[8] Xu L., Dalla Man C., Charbonnel B., Et al., Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: A model-based approach, Diabetes Obes Metab., 10, pp. 1212-1220, (2008)
[9] Brazg R., Xu L., Dalla Man C., Cobelli C., Thomas K., Stein P.P., Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes, Diabetes Obes Metab., 9, pp. 186-193, (2007)
[10] Drucker D.J., Nauck M.A., The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet., 368, pp. 1696-1705, (2006)

← 1 2 3 →